Sam has over 25 years' experience in the Life Sciences sector as an entrepreneur, CEO and investment manager.

‍He is currently Managing Partner at IP Group plc., the FTSE 250 investor, where he oversees the group's c.£500m Life Sciences portfolio. He is founding CEO and Chairman of Istesso Ltd, a Phase 2 drug-discovery company, and has served as founding investor, director and/or chairman of several leading UK private and public biotech businesses, including Diurnal Group plc, Pulmocide Ltd, Apollo Therapeutics, Genomics plc and Akamis Ltd.

Before founding Istesso, Sam was a top-ranked equity analyst in the City of London covering the biotechnology sector. Sam conducted his PhD and post-doctoral research in the Cambridge laboratory of Nobel Prize winner, Sir Gregory Winter, and he has a degree in biology from Oxford.